- Home
- CNF vs AEON Comparison
CNF vs AEON Comparison
Compare CNF & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | AEON |
|---|---|---|
| Founded | 1999 | N/A |
| Country | China | United States |
| Employees | N/A | 8 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 25.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNF | AEON |
|---|---|---|
| Price | $2.85 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 2.8K | ★ 143.1K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.39 |
| 52 Week High | $24.00 | $1.45 |
Technical Indicators
Market Signals| Indicator | CNF | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 53.79 |
| Support Level | $2.72 | $1.01 |
| Resistance Level | $5.13 | $1.12 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 25.87 | 77.17 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.